Trial reportPloS one2018
Pattern of risks of rheumatoid arthritis among patients using statins: A cohort study with the clinical practice research datalink.
Trial report in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Does the use of statins alter the risk of rheumatoid arthritis? A systematic review and meta-analysis.PloS one · 2024Pooled it
- Effect of statin use on the risk of rheumatoid arthritis: A systematic review and meta-analysis.Seminars in arthritis and rheumatism · 2020Pooled it
- Prevalence of Cardiovascular Comorbidities in Patients with Rheumatoid Arthritis.Medicina (Kaunas, Lithuania) · 2023Article
- Association of HMGCR inhibition with rheumatoid arthritis: a Mendelian randomization and colocalization study.Frontiers in endocrinology · 2023Article
- Incident Rheumatoid Arthritis Following Statin Use: From the View of a National Cohort Study in Korea.Journal of personalized medicine · 2022Article
- Cardiovascular Risk Prediction Parameters for Better Management in Rheumatic Diseases.Healthcare (Basel, Switzerland) · 2022Review
- Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment.Frontiers in immunology · 2022Review
- Risk of rheumatoid arthritis diagnosis in statin users in a large nationwide US study.Arthritis research & therapy · 2021Article
- Etiology and Risk Factors for Rheumatoid Arthritis: A State-of-the-Art Review.Frontiers in medicine · 2021Review
- Cardiac and vascular complications in rheumatoid arthritis.Reumatologia · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We examined the association between statin use and the risk of rheumatoid arthritis (RA), with special focus on describing the patterns of risks of RA during statin exposure in a large population-based cohort in the United Kingdom. In the Clinical Practice Research Datalink, patients aged ≥40 years with at least one prescription of statins (1995-2009) were selected, and matched by age (+/-5 years), sex, practice and date of first prescription of statins to non-users. The follow-up period of statin use was divided into periods of current, recent and past exposure, with patients moving between these three exposure categories over time. Time-dependent Cox models were used to derive hazard ratios (HRs) of RA, adjusted for disease history and previous drug use. The study population included 1,023,240 patients, of whom 511,620 were statin users. No associations were found between RA and current (HRadj,1.06;99%CI:0.88-1.27) or past statin users (HRadj,1.18;99%CI:0.88-1.57). However, in patients who currently used statins, hazard rates were increased shortly after the first prescription of statins and then gradually decreased to baseline level. The risk of developing RA was increased in recent statin users, as compared to non-users (HRadj,1.39;99%CI:1.01-1.90). The risk of RA is substantially increased in the first year after the start of statins and then diminishes to baseline level. These findings may suggest that statins might accelerate disease onset in patients susceptible to develop RA, but in other patients, statins are probably safe and well tolerated, even after prolonged use. Alternatively, we cannot rule out that confounding by cardiovascular risk factors and ascertainment bias may have influenced the findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.